A New Vaccine for West Nile Virus Using Influenza Virus
Author Information
Author(s): Martina Byron E. E., van den Doel Petra, Koraka Penelope, van Amerongen Geert, Spohn Gunther, Haagmans Bart L., Provacia Lisette B. V., Osterhaus Albert D. M. E., Rimmelzwaan Guus F.
Primary Institution: Erasmus MC, Rotterdam, The Netherlands
Hypothesis
The multimeric expression of DIII on recombinant influenza virus-infected cells would increase its immunogenicity, resulting in the induction of high titers of WNV neutralizing antibodies.
Conclusion
The study concluded that the recombinant influenza virus expressing WNV DIII is a promising approach for developing a bivalent vaccine against both WNV and influenza.
Supporting Evidence
- Vaccinated mice showed 100% protection against severe body weight loss and mortality from WNV.
- One subcutaneous immunization with 105 TCID50 Flu-NA-DIII provided complete protection.
- Protection was mediated by antibodies and CD4+ T cells.
Takeaway
Researchers created a new vaccine using a modified flu virus to help protect against West Nile virus, and it worked really well in mice.
Methodology
Mice were vaccinated with a recombinant influenza virus expressing WNV DIII and then challenged with WNV to assess protection.
Potential Biases
Potential conflicts of interest due to affiliations of some authors with biotechnology companies.
Limitations
The study was conducted in a mouse model, which may not fully represent human responses.
Participant Demographics
C57BL/6 mice were used in the experiments.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website